WallStSmart

Lineage, Inc. Common Stock (LINE)vsWelltower Inc (WELL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Welltower Inc generates 138% more annual revenue ($12.76B vs $5.36B). WELL leads profitability with a 12.1% profit margin vs -2.7%. WELL earns a higher WallStSmart Score of 57/100 (C).

LINE

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 2/9Altman Z: 0.67

WELL

Buy

57

out of 100

Grade: C

Growth: 10.0Profit: 5.5Value: 2.0Quality: 6.3
Piotroski: 4/9Altman Z: 1.20
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LINE.

WELLSignificantly Overvalued (-89.9%)

Margin of Safety

-89.9%

Fair Value

$124.92

Current Price

$236.92

$112.00 premium

UndervaluedFair: $124.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

WELL4 strengths · Avg: 9.3/10
Revenue GrowthGrowth
39.1%10/10

Revenue surging 39.1% year-over-year

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Market CapQuality
$166.86B9/10

Large-cap with strong market position

EPS GrowthGrowth
35.6%8/10

Earnings expanding 35.6% YoY

Areas to Watch

LINE4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.4%4/10

0.4% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

Debt/EquityHealth
1.013/10

Elevated debt levels

WELL4 concerns · Avg: 2.3/10
Return on EquityProfitability
3.3%3/10

ROE of 3.3% — below average capital efficiency

PEG RatioValuation
3.622/10

Expensive relative to growth rate

P/E RatioValuation
103.4x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.202/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : WELL

The strongest argument for WELL centers on Revenue Growth, Debt/Equity, Market Cap. Revenue growth of 39.1% demonstrates continued momentum.

Bear Case : LINE

The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.

Bear Case : WELL

The primary concerns for WELL are Return on Equity, PEG Ratio, P/E Ratio. A P/E of 103.4x leaves little room for execution misses.

Key Dynamics to Monitor

LINE profiles as a turnaround stock while WELL is a growth play — different risk/reward profiles.

LINE carries more volatility with a beta of 0.91 — expect wider price swings.

WELL is growing revenue faster at 39.1% — sustainability is the question.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WELL scores higher overall (57/100 vs 36/100) and 39.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.

Visit Website →

Welltower Inc

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

Welltower Inc. is a real estate investment trust that invests in healthcare infrastructure.

Visit Website →

Want to dig deeper into these stocks?